CMMB

NASDAQ

Chemomab Therapeutics Ltd.

SectorHealth CareIndustryBiotechnology: Pharmaceutical PreparationsIPO2019

News25/Ratings5

Chemomab Therapeutics Ltd. engages in the research and development of biological drugs for the treatment of inflammatory and fibrotic diseases. The company was formerly known as Anchiano Therapeutics Ltd. and changed its name to Chemomab Therapeutics Ltd. in March 16, 2021. Chemomab Therapeutics Ltd. was incorporated in 2011 and is based in Tel Aviv, Israel.

News · 26 weeks17+167%

2025-10-262026-04-19

Mix1390d

Insider8(62%)
Other3(23%)
SEC Filings2(15%)

Latest news

25 items

13dINSIDER
SEC Form 3 filed by new insider Mor George Adi
3 - Chemomab Therapeutics Ltd. (0001534248) (Issuer)
13dINSIDER
SEC Form 3 filed by new insider Darvish Nissim
3 - Chemomab Therapeutics Ltd. (0001534248) (Issuer)
13dINSIDER
SEC Form 3 filed by new insider Cohen Neil Harris
3 - Chemomab Therapeutics Ltd. (0001534248) (Issuer)
13dINSIDER
SEC Form 3 filed by new insider Moses Alan Charles
3 - Chemomab Therapeutics Ltd. (0001534248) (Issuer)
13dINSIDER
SEC Form 3 filed by new insider Fatal Sigal
3 - Chemomab Therapeutics Ltd. (0001534248) (Issuer)
13dINSIDER
SEC Form 3 filed by new insider Lawler John
3 - Chemomab Therapeutics Ltd. (0001534248) (Issuer)
23dINSIDER
SEC Form 3 filed by new insider Quigley Jill M.
3 - Chemomab Therapeutics Ltd. (0001534248) (Issuer)
23dINSIDER
SEC Form 3 filed by new insider Nicaise Claude
3 - Chemomab Therapeutics Ltd. (0001534248) (Issuer)
31dSEC
SEC Form 20-F filed by Chemomab Therapeutics Ltd.
20-F - Chemomab Therapeutics Ltd. (0001534248) (Filer)
34dSEC
SEC Form 6-K filed by Chemomab Therapeutics Ltd.
6-K - Chemomab Therapeutics Ltd. (0001534248) (Filer)
35dSEC
SEC Form 6-K filed by Chemomab Therapeutics Ltd.
6-K - Chemomab Therapeutics Ltd. (0001534248) (Filer)
65dSEC
Amendment: SEC Form SCHEDULE 13G/A filed by Chemomab Therapeutics Ltd.
SCHEDULE 13G/A - Chemomab Therapeutics Ltd. (0001534248) (Subject)
65dPR
Chemomab Therapeutics to Participate in Oppenheimer 36th Annual Healthcare Life Sciences Conference
TEL AVIV, Israel, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (NASDAQ:CMMB) (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced that CEO Dr. Adi Mor and other members of its senior management team will deliver a corporate presentation and participate in one-on-one investor meetings at the virtual Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 26, 2026. The corporate presentation will be webcast live and will be available at the investor relations section of the Chemomab website for 90 days. Oppenheimer 36th Annual Healthcare Life Sciences Confere
142dPR
Chemomab Therapeutics Announces Nebokitug Phase 2 SPRING Trial Results in Primary Sclerosing Cholangitis Published in the American Journal of Gastroenterology
—New Peer-Reviewed Publication Highlights Phase 2 SPRING Trial Data Supporting the Disease Modifying Potential of Nebokitug in PSC and Supports Advancement to a Phase 3 Registration Trial— TEL AVIV, Israel, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (NASDAQ:CMMB), (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced that the results of its Phase 2 SPRING trial assessing nebokitug in patients with primary sclerosing cholangitis (PSC) were published in the current issue of the American Journal of Gastroenterology.1 The study showed that nebokitug was generally safe and w
150dPR
Chemomab to Participate in Oppenheimer's Movers in Rare Disease Summit
TEL AVIV, Israel, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (NASDAQ:CMMB) (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced that co-founder and CEO Adi Mor, PhD, will participate in Oppenheimer's Movers in Rare Disease Summit on Thursday, December 11, 2025, at the Sofitel Hotel in New York City. The invitation-only Rare Disease Summit will feature a day of panels, presentations and 1-on-1 investor meetings with companies working in the rare disease space. Dr. Mor will present a corporate overview and will be available for one-on-one meetings with registered attendee
153dSEC
SEC Form 6-K filed by Chemomab Therapeutics Ltd.
6-K - Chemomab Therapeutics Ltd. (0001534248) (Filer)
168dPR
Chemomab Announces Multiple Presentations at AASLD The Liver Meeting® 2025 Featuring Clinical Data from the Nebokitug Phase 2 Trial in Primary Sclerosing Cholangitis
— Phase 2 SPRING Trial Open Label Extension Showed Favorable Safety and Consistent Improvements in Key Biomarkers in PSC Patients Treated with Nebokitug for Up to 48 Weeks— —New Clinical Data Provides Insights on Nebokitug's Direct Macrophage-Mediated Mechanisms that Are Key to PSC Disease Progression— —All Three Presentations Have Been Designated as Posters of Distinction— TEL AVIV, Israel and WASHINGTON, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (NASDAQ:CMMB) (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced that abstracts that highlight new clinical data from t
244dSEC
SEC Form 6-K filed by Chemomab Therapeutics Ltd.
6-K - Chemomab Therapeutics Ltd. (0001534248) (Filer)
245dPR
Chemomab Therapeutics to Present at H.C. Wainwright 27th Annual Global Investment Conference
TEL AVIV, Israel, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (NASDAQ:CMMB) (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced that Chief Executive Officer Dr. Adi Mor will deliver a corporate presentation at the H.C. Wainwright 27th Annual Global Investment Conference. Dr. Mor's prerecorded presentation will be webcast and will be available starting on September 5, 2025 at 7:00 am ET. The link to access the webcast is included below and is also available at the Events section of the Chemomab website. Chemomab management will also be hosting 1x1 investor meetings during
252dSEC
SEC Form 6-K filed by Chemomab Therapeutics Ltd.
6-K - Chemomab Therapeutics Ltd. (0001534248) (Filer)
252dPR
Chemomab Therapeutics Announces Second Quarter 2025 Financial Results and Provides Corporate Update
—Phase 3 Preparations Ongoing as Company Continues to Advance Multiple Partnering Options for Executing the Nebokitug Phase 3 Program— —Phase 2 SPRING Trial Data Highlighting Nebokitug's Unique Anti-Fibrotic, Anti-Inflammatory and Anti-Cholestatic Effects in PSC Featured at Multiple Major Scientific Meetings— —FDA and Chemomab Align on CMC and Non-Clinical Toxicology Regulatory Path Forward for Nebokitug—` —Cash Runway through End of Second Quarter of 2026— —Announces Plans to Implement ADS Ratio Change Adjustment— TEL AVIV, Israel, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (NASDAQ:CMMB), (Chemomab), a clinical stage biotechnology company developing innovative thera
259dSEC
Amendment: SEC Form SCHEDULE 13G/A filed by Chemomab Therapeutics Ltd.
SCHEDULE 13G/A - Chemomab Therapeutics Ltd. (0001534248) (Subject)
259dSEC
SEC Form SCHEDULE 13G filed by Chemomab Therapeutics Ltd.
SCHEDULE 13G - Chemomab Therapeutics Ltd. (0001534248) (Subject)
272dSEC
SEC Form 6-K filed by Chemomab Therapeutics Ltd.
6-K - Chemomab Therapeutics Ltd. (0001534248) (Filer)
272dSEC
SEC Form 424B5 filed by Chemomab Therapeutics Ltd.
424B5 - Chemomab Therapeutics Ltd. (0001534248) (Filer)